Header Logo

Connection

JENNIFER WARGO to B7-H1 Antigen

Back to Details
This is a "connection" page, showing publications JENNIFER WARGO has written about B7-H1 Antigen.
JENNIFER WARGO
Connection Strength
1.537
B7-H1 Antigen
  1. The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. Ann Surg Oncol. 2018 Jul; 25(7):1814-1827.
    View in: PubMed
    Score: 0.370
  2. Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. Clin Cancer Res. 2015 Jul 15; 21(14):3102-4.
    View in: PubMed
    Score: 0.305
  3. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. Clin Cancer Res. 2020 03 15; 26(6):1258-1266.
    View in: PubMed
    Score: 0.105
  4. Combination Immunotherapy Development in Melanoma. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:197-207.
    View in: PubMed
    Score: 0.094
  5. Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017 Jun 27; 117(1):1-7.
    View in: PubMed
    Score: 0.087
  6. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
    View in: PubMed
    Score: 0.087
  7. Immunotherapy resistance: the answers lie ahead - not in front - of us. J Immunother Cancer. 2017; 5:10.
    View in: PubMed
    Score: 0.086
  8. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.082
  9. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul; 2(7):643-54.
    View in: PubMed
    Score: 0.071
  10. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013 Feb 01; 19(3):598-609.
    View in: PubMed
    Score: 0.064
  11. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia. 2022 09; 31:100813.
    View in: PubMed
    Score: 0.031
  12. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
    View in: PubMed
    Score: 0.030
  13. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021 09 23; 12(1):5606.
    View in: PubMed
    Score: 0.030
  14. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020 01; 577(7791):561-565.
    View in: PubMed
    Score: 0.026
  15. Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 2019 Oct; 29(10):846-861.
    View in: PubMed
    Score: 0.026
  16. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018 06; 15(6):382-396.
    View in: PubMed
    Score: 0.024
  17. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.